Company news

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) news

Adaptive Biotechnologies Corporation news releases on 6ix. Latest, Sep 25, 2026: Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing…

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) news

Press releases & updates

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Adaptive Biotechnologies : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

Adaptive Biotechnologies : Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global Sales

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

Future in Tech Appoints Ed Moyle as Chief Information Security Officer

Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

Adaptive Announces IVDR Certification for clonoSEQ® in European Union

Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference